BRAFi/MEKi und ICI: Welche Nebenwirkungen sind zu erwarten?

[1] Heinzerling L et al.(2019) “Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management”,ESMO Open 2019; 4: e000491, DOI: 10.1136/esmoopen-2019-000491. eCollection 2019.

[2] 

Rosen L et al.(2011)” Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors”
 AACR 2011, Abstract 4716, DOI: https://doi.org/10.1158/1538-7445.AM2011-4716

[3] Mahmood SS et al.(2018) “Myocarditis in Patients Treated With Immune Checkpoint Inhibitors”J Am Coll Cardiol 2018; 71(16): 1755-1764, DOI: 10.1016/j.jacc.2018.02.037

[4] Sher AF et al.” Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis” Cancer Invest 2020; 38(2): 130-138, DOI: https://doi.org/10.1080/07357907.2020.1721521

[5] Schulz TU et al. Manuskript submitted